DIN 02369052 — APO-LAMIVUDINE 150 MG
APO-LAMIVUDINE is a tablet of Lamivudine marketed by APOTEX INC. The full Lamivudine monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02369052
- Brand name
- APO-LAMIVUDINE
- Active ingredient
- Lamivudine
- Strength
- 150 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- APOTEX INC
- Health Canada status
- MARKETED
- Drug class
- Nucleoside reverse transcriptase inhibitor (NRTI) / antiretroviral agent
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Lamivudine products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02192691 | 3TC | 10 MG | SOLUTION | VIIV HEALTHCARE ULC | MARKETED |
| 02192683 | 3TC | 150 MG | TABLET | VIIV HEALTHCARE ULC | MARKETED |
| 02247825 | 3TC | 300 MG | TABLET | VIIV HEALTHCARE ULC | MARKETED |
| 02369060 | APO-LAMIVUDINE | 300 MG | TABLET | APOTEX INC | MARKETED |
| 02393239 | APO-LAMIVUDINE HBV | 100 MG | TABLET | APOTEX INC | MARKETED |
| 02507110 | JAMP LAMIVUDINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |
| 02507129 | JAMP LAMIVUDINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |
| 02512467 | JAMP LAMIVUDINE HBV | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |